26 papers · ranked by Valyu relevance
Laura M. Arthur, Arran K. Turnbull, Lucy R. Khan, J. Michael Dixon
Purpose of Review Pre-operative endocrine therapy can be used to down-stage large or locally advanced breast cancers in ER+ disease. In the last four decades, it has evolved from a treatment perceived as an alternative to surgery for those too unfit to undergo surgery or chemotherapy, to the present day where it is a…
David A Potter, César A Herrera-Ponzanelli, Diego Hinojosa, Rafael Castillo + 4 more
Neoadjuvant trials for early breast cancer have accelerated the identification of novel active agents, enabling streamlined conduct of registration trials with fewer subjects. Measurement of neoadjuvant drug effects has also enabled the identification of patients with high risk of distant recurrence and has justified…
Yongxiao Wu, Shibo Huang, Yanlin Wei, Miaoyan Huang + 3 more
'Weiming Liang' 'Tian Qin'] Introduction The objective of this systematic review and network meta-analysis (NMA) is to assess the effectiveness and safety of various neoadjuvant treatment protocols in individuals diagnosed with hormone receptor-positive, her2 negative(HR+/HER2-) breast cancer. Materials and methods A…
Xiaofei Zhang, Ruoxin Lan, Yongjun Liu, Venu G Pillarisetty + 11 more
Neoadjuvant therapy (NAT) is increasingly used in the treatment of pancreatic ductal adenocarcinoma (PDAC). However, it is insufficiently understood how it differentially impacts carcinoma and tumor microenvironment (TME). We separately compared gene expression profiles in carcinoma and TME between NAT-treated versus…
Keith D. Amos, Barbara Adamo, Carey K. Anders
Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for…
Elizabeth Miller, Hee Jin Lee, Amriti Lulla, Liz Hernandez + 2 more
'Prashanth Gokare' 'Bora Lim'] Breast cancer is the most commonly diagnosed cancer in women. The latest world cancer statistics calculated by the International Agency for Research on Cancer (IARC) revealed that 1,677,000 women were diagnosed with breast cancer in 2012 and 577,000 died. The TNM classification of…
J. Lemieux, M. Clemons, L. Provencher, S. Dent + 8 more
'J. Mackey' 'K.I. Pritchard' 'D. Rayson' 'Sh. Verma' 'Su. Verma' 'B. Wang' 'S. Chia'] Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour…
P. Castorina, Daniela Carcò, Cristina Colarossi, M. Mare + 4 more
'Lorenzo Memeo' 'Marco Pace' 'Ivana Puliafito' 'Dario Giuffrida'] Neoadjuvant chemotherapy has been used for breast cancer aiming at downgrading before surgery. In this article we propose a new quantitative analysis of the effects of the neoadjuvant therapy to obtain numerical, personalized, predictions on the…
Elisabeth S. Bergen, Rupert Bartsch
Title: Summary A combination of anthracyclines and taxanes remains the standard of care for neoadjuvant chemotherapy (NACT) resulting in increased breast conservation rate (BCR) and decreased recurrence rate [1]. Whether pathological complete response (pCR) could be an appropriate surrogate parameter for long-term…
Hanna Piotrzkowska‐Wróblewska, Katarzyna Dobruch‐Sobczak, Ziemowit Klimonda, Piotr Karwat + 3 more
'Ziemowit Klimonda' 'Piotr Karwat' 'Katarzyna Roszkowska‐Purska' 'Magdalena Gumowska' 'Jerzy Litniewski'] Neoadjuvant chemotherapy (NAC) is used in patients with breast cancer to reduce tumor focus, metastatic risk, and patient mortality. Monitoring NAC effects is necessary to capture resistant patients and stop or…
Guillermo Lorenzo, Angela M. Jarrett, Christian T. Meyer, Vito Quaranta + 2 more
'Vito Quaranta' 'Darren R. Tyson' 'Thomas E. Yankeelov'] Neoadjuvant chemotherapy (NAC) is a standard-of-care treatment for locally advanced triple negative breast cancer (TNBC) before surgery. The early assessment of TNBC response to NAC would enable an oncologist to adapt the therapeutic plan of a non-responding…
Nikhitha Mule, Giulia Maffeis, Rinaldo Cubeddu, Carolina Santangelo + 3 more
'Giampaolo Bianchini' 'Pietro Panizza' 'Paola Taroni'] The purpose of this clinical study is to test broad spectral range (635-1060 nm) time domain diffuse optical spectroscopy in monitoring the response of breast cancer patients to neoadjuvant chemotherapy (NAC). The broadband operation allows us to fully analyze…
Christelle Bouchart, Oier Azurmendi Senar, Julie Navez, Laurine Verset + 18 more
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest tumors with slow progress in systemic therapies due to its peculiar and resistant tumor microenvironment. Inclusion of isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) into a total neoadjuvant strategy (TNT) is promising for the…
Muneer Ahmed, Felix Jozsa, Michael Douek
Introduction The use of neo-adjuvant radiotherapy (NRT) has been proven effective at improving cancer related outcome measures, including overall-survival (OS) in the management of solid cancers. However, its utilisation in breast cancer has not been explored to the extent of neo-adjuvant chemotherapy (NAC). The…
Shrey S. Sukhadia, Kristen E. Muller, Adrienne A. Workman, Shivashankar H. Nagaraj
Breast cancer ranks second in the most common cancer in women worldwide with 30% of cases resulting into recurrence of the disease at distant organs post the treatment. While clinicians have utilized several clinicopathological measurements for prediction of distant recurrences in invasive breast carcinoma (IBC), none…
Ariel I. Mundo, Abdussaboor Muhammad, Kerlin Balza, Christopher E. Nelson + 1 more
Metronomic chemotherapy (MET) has been developed to address the shortcomings of maximum-tolerated chemotherapy (MTD) in regard to toxicity and development of resistance mechanisms in the tumor. In colorectal cancer (CRC), MET is a promising novel strategy to treat locally advanced malignancies when used as neoadjuvant…
Gunilla Håwi, Peter Kim, Peter P. Lee
with neoadjuvant pembrolizumab using data-driven delay integro-differential equations Authors: ['Gunilla Håwi' 'Peter Kim' 'Peter P. Lee'] Colorectal cancer (CRC) poses a major public health challenge due to its increasing prevalence, particularly among younger populations, with it being the third most commonly…
Nathaniel Braman, Mohammed El Adoui, Manasa Vulchi, Paulette Turk + 9 more
'Maryam Etesami' 'Pingfu Fu' 'Kaustav Bera' 'Stylianos Drisis' 'Vinay Varadan' 'Donna Plecha' 'Mohammed Benjelloun' 'Jame Abraham' 'Anant Madabhushi'] Predicting response to neoadjuvant therapy is a vexing challenge in breast cancer. In this study, we evaluate the ability of deep learning to predict response to HER2…
Marta Bofill Roig, Yu Shen, Guadalupe Gómez Melis
Pathologic complete response (pCR) is a common primary endpoint for a phase II trial or even accelerated approval of neoadjuvant cancer therapy. If granted, a two-arm confirmatory trial is often required to demonstrate the efficacy with a time-to-event outcome such as overall survival. However, the design of a…
Liping Zhang, Ben Zhong Tang, Zheng Zhao, Yu Xiong + 8 more
Targeted and controllable drug release at lesion sites with the aid of visual navigation in real-time is of great significance for precise theranostics of cancers. Benefiting from the marvellous features (e.g. bright emission and phototheranostic effect in aggregates) of aggregation-induced emission (AIE) materials…
Nicholas Howell, Ryan J. Middleton, Frederic Sierro, Naomi A. Wyatt + 18 more
Neutron Capture Enhanced Particle Therapy (NCEPT) is a proposed augmentation of charged particle therapy which exploits thermal neutrons generated internally, within the treatment volume via nuclear fragmentation, to deliver a biochemically targeted radiation dose to cancer cells. This work is the first experimental…
Kavita Iyer, Julian Ivanov, Rumiana Tenchov, Krittika Ralhan + 4 more
Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel…
Hanan Babeker, Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Anjong Florence Tikum + 4 more
Nectin-4 is an overexpressed biomarker in 60-70% of triple-negative breast cancer (TNBC), and an ideal target for radiotherapy and PET imaging. In this study, we have developed theranostic radioimmunoconjugates (RICs) based on a fully-human anti-nectin-4 antibody, N4MU01. We characterized and evaluated the efficacy of…
Authors not listed
This conceptual framework proposes an out-of-the-box approach to innovate non-biological drugs that surpass biologics by 200-fold in efficacy and safety for cancer treatment. Integrating advanced paradigms from physics, chemistry, medicine, biology, engineering, and materials science, we delineate a multi-dimensional…
Authors not listed
Immuno-oncology, a rapidly evolving field at the forefront of cancer research, leverages the body’s immune system to fight cancer. In this follow up report, we extend our natural language processing (NLP)-based analysis to pinpoint the context of emergence of the previously identified emerging concepts. To achieve this…
HACHEMI KADRI, Mesk Alshatfa, Feras Z Alsalloum, Abdelbary Elhissi + 2 more
Cancer, a global health burden, is characterized by uncontrolled cell growth and metastasis, often resulting in debilitating treatments and mortality. While conventional therapeutic strategies have improved survival rates, they are limited by challenges such as off-target toxicity and drug resistance. With their design…